1. Dysregulated Leukotriene Metabolism in Patients with COVID-19.
- Author
-
Doğan HO, Budak M, Doğan K, Zararsız GE, Yerlitaş Sİ, Bolat S, Şenol O, Büyüktuna SA, Pınarbaşı E, Sarıismailoğlu R, and Yavuz H
- Subjects
- Humans, Male, Middle Aged, Female, Aged, 5-Lipoxygenase-Activating Proteins metabolism, 5-Lipoxygenase-Activating Proteins genetics, Adult, RNA, Messenger genetics, RNA, Messenger metabolism, SARS-CoV-2, Cysteine blood, Cysteine metabolism, Intensive Care Units, COVID-19 metabolism, Leukotrienes metabolism, Leukotrienes blood, Receptors, Leukotriene metabolism, Receptors, Leukotriene genetics, Arachidonate 5-Lipoxygenase metabolism, Arachidonate 5-Lipoxygenase genetics
- Abstract
This study aimed to examine the leukotriene metabolism during COVID-19. In total, 180 participants were included in this study, of which 60 were healthy controls, 60 required intensive care units (ICU), and 60 did not require intensive care (non-ICU). The serum levels of 5-lipoxygenase (5-LO), 5-LO activating protein (ALOX5AP), and cysteinyl leukotriene (CYSLT) were measured, and the mRNA expression levels of 5-LO, ALOX5AP, and cysteinyl leukotriene receptor 1 (CYSLTR1) were investigated. Compared with the control group, both the non-ICU and ICU groups had lower levels of 5-LO and mRNA expression. ICU patients had lower levels of 5-LO and mRNA expression than non-ICU patients. CYSLTR1 mRNA expression was highest in the ICU group, followed by the non-ICU group, and healthy controls had the lowest mRNA expression levels. CYSLT levels were higher in the control group than in the non-ICU and ICU groups. CYSLTR1 expression was higher in patients than in controls; therefore, selective leukotriene receptor blockers can be used as treatment options. CYSLTR1 expression was higher in the ICU group than in the non-ICU group. Furthermore, CYSLTR1 mRNA expression may be a promising biomarker of COVID-19 severity.
- Published
- 2024
- Full Text
- View/download PDF